201 related articles for article (PubMed ID: 23466625)
1. Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro.
Nerreter T; Distler E; Köchel C; Einsele H; Herr W; Seggewiss-Bernhardt R
Exp Hematol; 2013 Jul; 41(7):604-614.e4. PubMed ID: 23466625
[TBL] [Abstract][Full Text] [Related]
2. Profound inhibition of antigen-specific T-cell effector functions by dasatinib.
Weichsel R; Dix C; Wooldridge L; Clement M; Fenton-May A; Sewell AK; Zezula J; Greiner E; Gostick E; Price DA; Einsele H; Seggewiss R
Clin Cancer Res; 2008 Apr; 14(8):2484-91. PubMed ID: 18413841
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens.
Fei F; Yu Y; Schmitt A; Rojewski MT; Chen B; Greiner J; Götz M; Guillaume P; Döhner H; Bunjes D; Schmitt M
Exp Hematol; 2008 Oct; 36(10):1297-308. PubMed ID: 18619726
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.
Fraser CK; Blake SJ; Diener KR; Lyons AB; Brown MP; Hughes TP; Hayball JD
Exp Hematol; 2009 Feb; 37(2):256-65. PubMed ID: 19056158
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells.
Fei F; Yu Y; Schmitt A; Rojewski MT; Chen B; Götz M; Döhner H; Bunjes D; Schmitt M
Br J Haematol; 2009 Jan; 144(2):195-205. PubMed ID: 19016717
[TBL] [Abstract][Full Text] [Related]
6. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon.
Faber LM; van Luxemburg-Heijs SA; Rijnbeek M; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 1996 Feb; 2(1):31-6. PubMed ID: 9078352
[TBL] [Abstract][Full Text] [Related]
7. Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study.
Uchiyama T; Sato N; Narita M; Yamahira A; Iwabuchi M; Furukawa T; Sone H; Takahashi M
Hematol Oncol; 2013 Sep; 31(3):156-63. PubMed ID: 23108877
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib.
Hassold N; Seystahl K; Kempf K; Urlaub D; Zekl M; Einsele H; Watzl C; Wischhusen J; Seggewiss-Bernhardt R
Int J Cancer; 2012 Sep; 131(6):E916-27. PubMed ID: 22419518
[TBL] [Abstract][Full Text] [Related]
10. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro.
Blake S; Hughes TP; Mayrhofer G; Lyons AB
Clin Immunol; 2008 Jun; 127(3):330-9. PubMed ID: 18395492
[TBL] [Abstract][Full Text] [Related]
11. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
12. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J
Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403
[TBL] [Abstract][Full Text] [Related]
13. Antigen-specific activation thresholds of CD8+ T cells are independent of IFN-I-mediated partial lymphocyte activation.
Wijesundara DK; Kumar S; Alsharifi M; Müllbacher A; Regner M
Int Immunol; 2010 Sep; 22(9):757-67. PubMed ID: 20682547
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous mechanisms of human cytotoxic T lymphocyte generation. II. Differential effects of IL-6 on the helper cell-independent generation of CTL from CD8+ precursor subpopulations.
Bass HZ; Yamashita N; Clement LT
J Immunol; 1993 Sep; 151(6):2895-903. PubMed ID: 8376760
[TBL] [Abstract][Full Text] [Related]
15. Multiple cytolytic mechanisms displayed by activated human peripheral blood T cell subsets.
Smyth MJ; Norihisa Y; Ortaldo JR
J Immunol; 1992 Jan; 148(1):55-62. PubMed ID: 1345790
[TBL] [Abstract][Full Text] [Related]
16. Differential responses of invariant V alpha 24J alpha Q T cells and MHC class II-restricted CD4+ T cells to dexamethasone.
Milner JD; Kent SC; Ashley TA; Wilson SB; Strominger JL; Hafler DA
J Immunol; 1999 Sep; 163(5):2522-9. PubMed ID: 10452989
[TBL] [Abstract][Full Text] [Related]
17. Human atopen-specific types 1 and 2 T helper cell clones.
Wierenga EA; Snoek M; Jansen HM; Bos JD; van Lier RA; Kapsenberg ML
J Immunol; 1991 Nov; 147(9):2942-9. PubMed ID: 1680923
[TBL] [Abstract][Full Text] [Related]
18. Lovastatin inhibits T-cell proliferation while preserving the cytolytic function of EBV, CMV, and MART-1-specific CTLs.
Li D; Li Y; Hernandez JA; Patenia R; Kim TK; Khalili J; Dougherty MC; Hanley PJ; Bollard CM; Komanduri KV; Hwu P; Champlin RE; Radvanyi LG; Molldrem JJ; Ma Q
J Immunother; 2010; 33(9):975-82. PubMed ID: 20948439
[TBL] [Abstract][Full Text] [Related]
19. Normal hematopoietic progenitor cells and malignant lymphohematopoietic cells show different susceptibility to direct cell-mediated MHC-non-restricted lysis by T cell receptor-/CD3-, T cell receptor gamma delta+/CD3+ and T cell receptor-alpha beta+/CD3+ lymphocytes.
Voogt PJ; Falkenburg JH; Fibbe WE; Veenhof WF; Hamilton M; Van Krimpen BA; Bolhuis RL
J Immunol; 1989 Mar; 142(5):1774-80. PubMed ID: 2521886
[TBL] [Abstract][Full Text] [Related]
20. Exogenous immunoglobulin downregulates T-cell receptor signaling and cytokine production.
Tawfik DS; Cowan KR; Walsh AM; Hamilton WS; Goldman FD
Pediatr Allergy Immunol; 2012 Feb; 23(1):88-95. PubMed ID: 21265884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
